Sanofi India Limited
Sanofi India Limited appointed Mr. Rahul Bhatnagar as the Chairman of its Board of Directors, effective April 30, 2026. He brings extensive experience in finance, strategy, and governance.
Apr 30 2026 16:04:00
Sanofi India Limited
Sanofi India's 70th Annual General Meeting concluded with the approval of a total dividend of Rs.123 per share for the financial year ended December 31, 2025. The meeting also approved the appointment of Rahul Bhatnagar as Chairman and Sudipta Chakraborty as Whole-time Director, effective April 30, 2026, along with ratification of material related party transactions.
Apr 29 2026 20:04:00
Sanofi India Limited
Sanofi India shareholders approved the appointment of Ms. Sudipta Chakraborty as Whole-time Director. The company also secured approval for two material related party transactions and declared a final dividend of Rs.48 per equity share for FY25.
Apr 29 2026 20:04:00
Sanofi India Limited
Sanofi India's board appointed Rahul Bhatnagar as Chairman, effective April 30, 2026. The board also noted the tenure completion of Independent Directors Aditya Narayan and Usha Thorat on April 29, 2026.
Apr 28 2026 20:04:00
Sanofi India Limited
Sanofi India's board appointed Rahul Bhatnagar as Chairman, effective April 30, 2026. The board also noted the tenure completion of Independent Directors Aditya Narayan and Usha Thorat on April 29, 2026.
Apr 28 2026 19:04:00
Sanofi India Limited
Sanofi India's board approved Q4 FY26 results with revenue of ₹472.3 crore and net profit of ₹102.6 crore. The insulin portfolio showed strong double-digit growth. Additionally, Mr. Rahul Bhatnagar has been appointed as the new Chairman of the Board.
Apr 28 2026 19:04:00
Sanofi India Limited
Sanofi India's board approved Q4 FY26 results with revenue of ₹472.3 crore and net profit of ₹102.6 crore. The insulin portfolio showed strong double-digit growth. Additionally, Mr. Rahul Bhatnagar has been appointed as the new Chairman of the Board.
Apr 28 2026 18:04:00
Sanofi India Limited
Sanofi India's board approved Q4 FY26 results with revenue of ₹472.3 crore and net profit of ₹102.6 crore. The insulin portfolio showed strong double-digit growth. Additionally, Mr. Rahul Bhatnagar has been appointed as the new Chairman of the Board.
Apr 28 2026 18:04:00
Sanofi India Limited
Sanofi India's board approved Q4 FY26 results with revenue of ₹472.3 crore and net profit of ₹102.6 crore. The insulin portfolio showed strong double-digit growth. Additionally, Mr. Rahul Bhatnagar has been appointed as the new Chairman of the Board.
Apr 28 2026 18:04:00
Sanofi India Ltd - 500674 - Board Meeting Outcome for Of The Board Meeting Of The Company
Sanofi India reported Q1 FY26 revenue of ₹472.3 crores, a decrease of 11.88% YoY, and net profit of ₹102.6 crores, down 14.14% YoY. The company's insulin portfolio showed double-digit growth, and Mr. Rahul Bhatnagar was appointed as Chairman of the Board effective April 30, 2026.
Apr 28 2026 18:04:00
Read More